Neurodegenerative Diseases
194 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| [F-18]Flornaptitril for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 120 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz Synchronous Audio-Visual Stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 60 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aav-gad for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1005 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa PC+S Neurostimulator for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD04 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD5-NCOV for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS (aDBS) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS delivered through AlphaDBS IPG System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive deep brain stimulation + conventional deep brain stimulation for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| aDBS-Extended (Medtronic Percept™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aducanumab for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Ambroxol for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol hydrochloride for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apitegromab for spinal muscular atrophies of childhood | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| apomorphine infusion for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTN201 Focused Ultrasound to the CMN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atuzaginstat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dopaminergic cell implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous midbrain dopamine neurons for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBB opening for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 225 mg for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Brain Barrier (BBB) Disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Buntanetap for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap tartrate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Capivasertib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphatic Microsurgery for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined metabolic activators for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for corticobasal degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for multiple system atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVN424 150 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CVN424 75 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DC-LVA treatment plus usual care for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, DBS for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis, LVA for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphovenous anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for dysautonomia, familial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet + Exercise + Meditation for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Donanemab for lewy body disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Dexamethasone for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DSP-1083 implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elraglusib for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emestedastat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etanercept for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ExAblate 4000 Type 2.1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Facilitate tDCS + CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasudil for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLORTAUCIPIR F-18 for neurodegenerative diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gam-COVID-Vac for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GammaSense Stimulation device for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gantenerumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| GC101 for muscular atrophy, spinal | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GENUS device (Active Settings) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GV-971 for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| GV-971 + MEMANTINE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-Intensity Aerobic Exercise (AE) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-64042056 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lecanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| LECANEMAB + Etalanetug for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lixisenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low intensity focused ultrasound (LIFU) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-IV for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-SC for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3884961 + Sirolimus + Methylprednisolone for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo (E2814) + LECANEMAB for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Memantine for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Metformin for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mevidalen for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MK-1167 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MR guided low intensity focused ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NanoLithium® NP03 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMS-01 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OAV101 for bulbo-spinal atrophy, x-linked | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Obicetrapib 10 mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linked | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onasemnogene abeparvovec for muscular atrophy, spinal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Onasemnogene abeparvovec for spinal muscular atrophies of childhood | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PBT-434 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEMBROLIZUMAB + Porustobart for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 high dose (15 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 low dose (1 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 1 (3 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 2 (7 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + ADUCANUMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Placebo + Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasinezumab for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Psilocybin for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin + PIMAVANSERIN for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risdiplam for muscular atrophy, spinal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| ROC-101 for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semagludtide for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simufilam for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| SKG0201 Injection for spinal muscular atrophies of childhood | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 600mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium Oligomannate Capsules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solanezumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhood | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tACS combined with 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tavapadon for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TEV-56286 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| The LFP Beta aDBS System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Transcranial alternating current stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Troculeucel for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trontinemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Valacyclovir for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valiltramiprosate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VCA-894A for charcot-marie-tooth disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wujia Yizhi granules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YA-101 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |